Sort   by:  
 Page size 
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress
TranscriptomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63582 | biostudies-arrayexpress
ProteomicsThe Lin28b/Wnt5a axis drives pancreas cancer through crosstalk between cancer associated fibroblasts and tumor epithelium
Bidirectional signal transduction between tumor epithelial cells and tumor microenvironment (TME) is important for tumor development. Here we showed that Lin28b/let-7 pathway is indispensable for modulating the expression of Wnt5a in tumor epithelium, which could be secreted and then up-regulates Li...
ORGANISM(S): Mus Musculus 
2023-09-19 | PXD045477 |
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress
Sort   by:  
 Page size